Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
- 1 July 2014
- journal article
- Published by Elsevier BV in Cytotherapy
- Vol. 16 (7), 946-964
- https://doi.org/10.1016/j.jcyt.2014.02.017
Abstract
No abstract availableKeywords
Funding Information
- IZKF
- BayImmunet
- Olivia Hendrickx Research Fund
- Herman Memorial Research Fund
- James E. Kearney Foundation
- CAF Belgium, Baxter
- IWT (TBM projects)
- Stem Cell Institute Leuven
- Emmanuel van der Schueren Fund
- International Union Against Cancer
- Klinisch Onderzoeksfonds UZ Leuven
This publication has 60 references indexed in Scilit:
- IL-12p70–producing patient DC vaccine elicits Tc1-polarized immunityJCI Insight, 2013
- α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trialBMC Cancer, 2012
- An Optimized Method for Manufacturing a Clinical Scale Dendritic Cell-Based Vaccine for the Treatment of GlioblastomaPLOS ONE, 2012
- Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10–producing suppressive CD4+ T cellsThe Journal of Experimental Medicine, 2012
- Induction of CD8+T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant GliomaJournal of Clinical Oncology, 2011
- Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapyCancer Immunology, Immunotherapy, 2010
- Immunotherapy Approaches for Malignant Glioma From 2007 to 2009Current Neurology and Neuroscience Reports, 2010
- Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donorsVaccine, 2009
- Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma MultiformeClinical Cancer Research, 2008
- Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migrationCancer Immunology, Immunotherapy, 2008